F10 and Thromboembolism: Rivaroxaban, a direct factor-Xa inhibitor approved forvenous thromboembolism treatment/prevention, was chosen because of its easyadministration compared to the subcutaneous and intravenous forms of heparin productsand quick action and fewer drug interactions compared to warfarin.